Moreover, targeted therapy (e.g., epidermal growth factor receptor [EGFR] tyrosine kinase inhibitors) has been used to treat recurrent and advanced NSCLC since 200316, 17 and is the most effective in the ADC subtype, particularly in tumors with EGFR mutations.18 This evidence concerns the gene EGFR and non-small cell lung carcinoma.